Nektar Therapeutics NKTR
NASDAQ NKTR
$59.29 -1.11 (-1.84%)
As of: Sep 29, 2026 · 3:59 PM EDT

Nektar Therapeutics (NKTR) EBITDA Margin (2010 - 2026)

Updated

Nektar Therapeutics (NKTR) recorded EBITDA Margin of -416.40% in Q2 2026, down 94.10 percentage points from -322.29% a year earlier and down 58.21 percentage points from the prior quarter.

Analysis

Nektar Therapeutics (NKTR) EBITDA Margin (2010 - 2026) Analysis & Trends

On a TTM basis, Nektar Therapeutics' EBITDA Margin came in at -256.53% as of Jun 30, 2026, down 124.69 percentage points year-over-year; for FY2025, it was -251.80%, down 149.39 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of +16.93 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -102.42% in FY2024 (+181.50 pp), -283.91% in FY2023 (+110.56 pp), -394.48% in FY2022 (+29.40 pp) and -423.87% in FY2021 (-155.14 pp).
  • The Q2 2026 figure is the lowest quarterly EBITDA Margin since Q1 2025.
  • On a year-over-year basis, EBITDA Margin rose in three of the last eight quarters, with an average year-over-year change of -61.67 percentage points.
  • Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 456.88 percentage points in Q1 2024, against a drop of 315.64 percentage points in Q2 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at -358.19% (Q1 2026), -125.99% (Q4 2025) and -266.97% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Nektar Therapeutics 2.00 Bn 227.61 Mn - -416.40%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -416.40%
Mar 31, 2026 -358.19%
Dec 31, 2025 -125.99%
Sep 30, 2025 -266.97%
Jun 30, 2025 -322.29%
Mar 31, 2025 -421.69%
Dec 31, 2024 50.32%
Sep 30, 2024 -138.25%
Jun 30, 2024 -205.69%
Mar 31, 2024 -156.29%
Dec 31, 2023 -133.38%
Sep 30, 2023 -178.80%
Jun 30, 2023 -236.27%
Mar 31, 2023 -613.17%
Dec 31, 2022 -223.80%
Sep 30, 2022 -218.51%
Jun 30, 2022 -692.12%
Mar 31, 2022 -454.56%
Dec 31, 2021 -437.74%
Sep 30, 2021 -441.30%
API Access

Nektar Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NKTR&period=max&api_key=YOUR_API_KEY